Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct;15(4):454-460.
doi: 10.3988/jcn.2019.15.4.454.

High Seroprevalence and Index of Anti-John-Cunningham Virus Antibodies in Korean Patients with Multiple Sclerosis

Su Hyun Kim  1 , Yeseul Kim  1 , Ji Yun Jung  1 , Na Young Park  1 , Hyunmin Jang  1 , Jae Won Hyun  1 , Ho Jin Kim  2
Affiliations

High Seroprevalence and Index of Anti-John-Cunningham Virus Antibodies in Korean Patients with Multiple Sclerosis

Su Hyun Kim et al. J Clin Neurol. 2019 Oct.

Erratum in

Abstract

Background and purpose: The anti-John-Cunningham virus (JCV)-antibody serostatus and index are used in the risk stratification of progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS) patients treated with natalizumab. However, little information on these parameters is available for Asian countries. The purpose of this study was to determine the rate of seropositivity, index, and longitudinal index evolution in Korean patients with MS.

Methods: The antibody seroprevalence was analyzed in 355 samples from 187 patients with clinically isolated syndrome or MS using a second-generation, two-step, enzyme-linked immunosorbent assay. A 4-year longitudinal evaluation was applied to 66 patients.

Results: The overall antibody seroprevalence was 80% (n=149). Among antibody-positive patients, the index had a median value of 3.27 (interquartile range, 1.52-4.18), with 77% (n=114) and 56% (n=83) of patients having indices >1.5 and >3.0, respectively. The serostatus of 59 (89%) of the 66 patients did not change during the longitudinal analysis, while 3 (6%) of the 53 patients who were initially seropositive reverted to seronegativity, and 2 (15%) of the 13 patients who were initially seronegative converted to seropositivity. All patients with a baseline index >0.9 maintained seropositivity, and 92% of patients with a baseline index >1.5 maintained this index over 4 years. No patients developed PML (median disease duration, 8 years).

Conclusions: The seroprevalence and index of anti-JCV antibodies in Korean patients with MS may be higher than those in Western countries.

Keywords: Asia; John Cunningham virus; antibodies; index; progressive multifocal leukoencephalopathy.

PubMed Disclaimer

Conflict of interest statement

The authors have no potential conflicts of interest to disclose.

Figures

Fig. 1
Fig. 1. Anti-JCV antibody index level in patients with multiple sclerosis. A: Anti-JCV-antibody index at baseline in seropositive patients. Dashed line and horizontal bars indicate the median and interquartile-range values, respectively. B: Anti-JCV-antibody index of seropositive patients with multiple sclerosis. The indices of anti-JCV-antibody-positive patients did not increase with age. JCV: John-Cunningham virus.
Fig. 2
Fig. 2. Serial assessment of anti-JCV-antibody indices of patients who were seropositive at baseline (two to seven JCV serology assessments were performed in each patient). A: Patients with anti-JCV indices >1.5. B: Patients with anti-JCV indices ≤1.5. Horizontal dashed lines indicate indices of 0.2, 0.4, and 1.5. JCV: John-Cunningham virus.
See this image and copyright information in PMC

References

    1. Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366:1870–1880. - PubMed
    1. Plavina T, Subramanyam M, Bloomgren G, Richman S, Pace A, Lee S, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2014;76:802–812. - PMC - PubMed
    1. Ho PR, Koendgen H, Campbell N, Haddock B, Richman S, Chang I. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol. 2017;16:925–933. - PubMed
    1. Correia I, Jesus-Ribeiro J, Batista S, Martins AI, Nunes C, Macário MC, et al. Anti-JCV antibody serostatus and longitudinal evaluation in a Portuguese multiple sclerosis population. J Clin Neurosci. 2017;45:257–260. - PubMed
    1. Dominguez-Mozo MI, Rus M, Santiago JL, Izquierdo G, Casanova I, Galan V, et al. Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort. Eur J Clin Invest. 2017;47:158–166. - PubMed